Latest news with #CLL
Business Upturn
a day ago
- Business
- Business Upturn
Zydus Lifesciences gets tentative approval from USFDA for Ibrutinib tablets
Zydus Lifesciences has received tentative approval from the USFDA to market Ibrutinib tablets in the 140 mg, 280 mg, and 420 mg strengths in the U.S. market. The drug is a generic version of Imbruvica® and is used in treating adult patients with Chronic Lymphocytic Leukaemia (CLL)/Small Lymphocytic Lymphoma (SLL) with 17p deletion, as well as Waldenstrom's Macroglobulinemia (WM). The tablets will be manufactured at Zydus' SEZ facility in Ahmedabad. According to IQVIA (MAT May 2025), Ibrutinib tablets clocked annual sales of USD 2.15 billion in the U.S. With this, Zydus now holds 420 approvals and has filed 484 ANDAs since it began filings in FY 2003-04. In the meantime, Zydus Lifesciences shares opened today at ₹962.95 and, at the time of writing, touched a high of ₹976.60 during the session. The stock also hit a low of ₹960.15 in intraday trade. Over the past year, Zydus shares have seen a 52-week high of ₹1,324.30 and a low of ₹795.00. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Medscape
2 days ago
- Health
- Medscape
Novel Agents Transform Double-Refractory CLL Care
TOPLINE: Noncovalent Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib and chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel have gained FDA approval for double-refractory chronic lymphocytic leukemia (CLL). Novel BTK-directed therapies and T-cell-engaging bispecific antibodies demonstrate promising responses in early-phase trials for pretreated CLL. METHODOLOGY: Researchers conducted a comprehensive review of mechanisms responsible for resistance to covalent BTK inhibitors and B-cell lymphoma 2 inhibitor (BCL-2i) venetoclax in CLL. Analysis included evaluation of recent evidence supporting novel and emerging agent classes, including noncovalent BTK inhibitors, CAR T-cell therapy, and T-cell-engaging bispecific antibodies. Investigators examined treatment strategies incorporating these therapies in patients with double-refractory disease, considering variability in access to novel therapies and clinical trials. TAKEAWAY: Pirtobrutinib demonstrated an overall response rate of 72% in patients with chronic lymphocytic leukemia, with a median progression-free survival of 14 months compared with 8.7 months for control therapies. Lisocabtagene maraleucel achieved an overall response rate of 44% in double-refractory patients, with grade ≥ 3 cytokine release syndrome occurring in 8% and neurologic events in 19% of patients. BTK degraders showed promising early results, with BGB-16673 achieving responses in heavily pretreated patients, most of whom (92%) were exposed to covalent BTK inhibitors and BCL-2i. Epcoritamab demonstrated an overall response rate of 53% in double-exposed patients, with a complete response rate of 37% and undetectable measurable residual disease in two thirds of responders. IN PRACTICE: 'Within the current regulatory environment, either ncBTKi [noncovalent BTK inhibitor] or CAR T-cell therapy should be considered as first-line management for double-refractory disease, with the choice individualized based on disease stage, BTK mutational status, toxicity from prior therapies, performance status, comorbidities, and geographic and financial constraints,' the authors of the study wrote. SOURCE: This study was led by Brian T. Grainger of Sir Charles Gairdner Hospital in Nedlands, Australia. It was published online in Blood. LIMITATIONS: The literature describing CLL in the post-covalent BTK inhibitor and BCL-2i setting varies in criteria used to identify double-refractory patients, complicating assessment of disease prevalence and prognosis. Additionally, there were limited prospective data for outcomes following one class of targeted agent after disease progression on the other. DISCLOSURES: Philip A. Thompson disclosed relationships with AbbVie, Ascentage Pharma, AstraZeneca, BeiGene, Genentech, Genmab, Janssen Pharmaceuticals, Eli Lilly and Company, Merck, Adaptive Biotechnologies, Roche, and Sana Biotechnology. Additional disclosures were noted in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Rhyl Journal
2 days ago
- Entertainment
- Rhyl Journal
Jules Peters pays tribute to 'legend' Ozzy Osbourne
In 2018, Osbourne lent his support to Jules and Mike Peters' Love Hope Strength (LHS) Foundation, inviting the team to join his tour to help add more people to the stem cell donor registry Jules said: "Love Hope Strength has had some incredible supporters through the years, and continues to do so, some of whom have been very well known. All of whom have played an important role in helping fulfil LHS' mission to save lives one concert at a time. "We were so grateful when Ozzy Osbourne lent his voice to the Love Hope Strength Foundation back in 2018 and invited LHS to get folk on the list during his tour. He was kind, considerate gentleman as well as being a truly incredible rock star. "Despite being known as the Prince of Darkness, Ozzy brought a lot of light to people affected by blood cancer by helping people to become potential stem cell donors on his tour. "Sending love, hope and strength to Ozzy's family, friends and all who loved him and his music at this sad time." Music superstar Osbourne died at the age of 76 on July 22, just weeks after a Black Sabbath reunion concert held in his home city of Birmingham. RELATED STORIES Mike Peter's son to take to the stage at Lytham Festival PICTURES: Thousands attend funeral of Mike Peters in Dyserth RECAP: Final farewell to The Alarm's Mike Peters The singer, who had been diagnosed with Parkinson's disease in 2019, was 'with his family and surrounded by love'. A statement said: 'It is with more sadness than mere words can convey that we have to report that our beloved Ozzy Osbourne has passed away this morning. He was with his family and surrounded by love. We ask everyone to respect our family privacy at this time.' Earlier this month, Osbourne bid a farewell to fans with a Black Sabbath reunion, telling thousands of heavy metal enthusiasts at Villa Park, Birmingham – a stone's throw from where Black Sabbath was formed in 1968 – that it was 'so good to be on this stage' as he performed his last set from a large black throne. Osbourne and his fellow original Black Sabbath members – Tony Iommi, Terence 'Geezer' Butler and Bill Ward – were the last to appear on stage as part of the star-studded line-up for the Back to the Beginning concert. Rock star Mike, frontman of Welsh rock band The Alarm, died from blood cancer on April 29 aged 66 - more than 30 years after he was first diagnosed with chronic lymphocytic leukaemia (CLL) at the age of 36 The Love Hope Strength Foundations operate in the USA, UK and Australia. The foundation aims to "help save and change lives one concert, one step, one helping hand at a time" through partnering with cancer care specialists across the globe, and offering support to families affected by cancer. A key part of LHS's activities is to encourage people between the ages of 17 and 55 to register as blood stem cell donors.
Hans India
5 days ago
- Health
- Hans India
Exercise best bet for people with chronic lymphocytic leukaemia
Chronic lymphocytic leukaemia (CLL) is the most common adult blood cancer in the western world, and it predominantly affects older adults. Most people are diagnosed after the age of 70, but increasing numbers of younger people, some under 60, are also being affected. CLL starts when a type of immune cell called a B cell – normally responsible for producing antibodies – becomes cancerous. This not only stops it from working properly but also weakens the rest of the immune system. For many people, CLL begins as a slow-moving, low-grade disease that doesn't need immediate treatment. These patients are placed on 'active monitoring,' where they're regularly checked for signs of progression. Others, especially those with more aggressive forms of the disease, will need immediate and targeted treatment to destroy the cancer cells. But regardless of the stage, CLL involves a prolonged and often unpredictable course. It is associated with a higher risk of infections, secondary cancers and a heavy symptom burden that can affect quality of life for years. People on active monitoring often find themselves in a kind of medical limbo: well enough not to need treatment, but not well enough to feel secure. Fatigue, anxiety, social isolation and fear of infection are common. For those receiving treatment, side effects including nausea, bleeding, diarrhoea and extreme tiredness can make everyday life even more challenging. Because CLL weakens the body's ability to fight infection, many people begin avoiding places where germs might spread: busy shops, family gatherings, even the gym. But while this instinct is understandable, it can come at a cost. Over time, isolation and inactivity can chip away at physical fitness, reduce resilience and make it harder to recover from illness or cope with stress. The role of exercise is good for everyone but for people living with CLL, it can be life changing. Our research shows that physical activity is strongly linked to fewer symptoms and a better quality of life. Fatigue, the most common and often most debilitating symptom, was significantly lower in people who stayed active. Many also reported reduced pains and a greater sense of physical wellbeing. Cancer-related fatigue isn't just feeling a bit tired. It's a deep, persistent exhaustion that doesn't improve with sleep or rest. The exact biological reasons behind it aren't fully understood, but one thing is clear: regular movement helps. People who are more active tend to feel better – and live better. The good news is that even gentle activity can make a difference. Low-intensity activities are safe for almost everyone and come with meaningful health benefits. Walking, yoga, swimming – anything that gets you moving – can help ease symptoms. In fact, research shows that just 12 weeks of regular exercise can reduce fatigue and improve day-to-day wellbeing. People with additional health concerns, such as heart disease, diabetes or bone conditions, should take extra care. It's always a good idea to speak to a doctor or physiotherapist before starting a new routine. The PAR-Q+ (physical activity readiness questionnaire) is a helpful tool to assess whether it's safe to begin exercising. Once cleared, the goal is to work up to the recommended activity levels: 150–300 minutes of moderate activity a week (like brisk walking or cycling) or 75–150 minutes of vigorous activity (like jogging or swimming), along with two sessions of muscle-strengthening activities per week. Start slowly and build gradually. Because people with CLL are immunocompromised, it's important to reduce infection risks while staying active. That might mean exercising outdoors, avoiding crowds, wearing a mask, or choosing quieter times at the gym. But, if precautions are taken, the benefits of movement far outweigh the risks. Benefits of keeping active: In one of our pilot studies, people with CLL who had not yet started treatment showed smaller increases in tumour cell counts after 12 weeks of exercise. Their immune systems also appeared more robust, with stronger responses to abnormal cells. This research is still in its early stages, but it's encouraging to see that exercise doesn't appear to accelerate disease progression – and might even help to slow it. The biggest improvements were seen in people who started off with the worst symptoms or poorest physical condition. In other words, those with the most to gain, gained the most. Older adults seemed to benefit from even modest activity. People receiving treatment were generally less active and reported lower quality of life than those who weren't, but their symptom levels were similar. That suggests physical activity might offer especially meaningful benefits for people going through treatment. Exercise is already a well-established part of care for people with solid tumours such as breast or bowel cancer. What's different about CLL is that many people don't receive treatment for years – yet still experience symptoms and lower quality of life. Our study shows that physical activity matters just as much for this group. Whether someone is on active monitoring or undergoing treatment, staying active can help ease symptoms, boost energy and improve daily life. It's a powerful reminder that even small steps can make a big difference and that living well with CLL isn't just about waiting for treatment. It's about reclaiming strength and mobility, one movement at a time. (The writer is from University of Surrey)
Indian Express
6 days ago
- Health
- Indian Express
Exercise could ease symptoms for people with chronic lymphocytic leukaemia (CLL)
Chronic lymphocytic leukaemia (CLL) is the most common adult blood cancer in the western world, and it predominantly affects older adults. Most people are diagnosed after the age of 70, but increasing numbers of younger people, some under 60, are also being affected. CLL starts when a type of immune cell called a B cell – normally responsible for producing antibodies – becomes cancerous. This not only stops it from working properly, but also weakens the rest of the immune system. For many people, CLL begins as a slow-moving, low-grade disease that doesn't need immediate treatment. These patients are placed on 'active monitoring,' where they're regularly checked for signs of progression. Others, especially those with more aggressive forms of the disease, will need immediate and targeted treatment to destroy the cancer cells. But regardless of the stage, CLL involves a prolonged and often unpredictable course. It's associated with a higher risk of infections, secondary cancers and a heavy symptom burden that can affect quality of life for years. People on active monitoring often find themselves in a kind of medical limbo: well enough not to need treatment, but not well enough to feel secure. Fatigue, anxiety, social isolation and fear of infection are common. For those receiving treatment, side effects including nausea, bleeding, diarrhoea and extreme tiredness can make everyday life even more challenging. Because CLL weakens the body's ability to fight infection, many people begin avoiding places where germs might spread: busy shops, family gatherings, even the gym. But while this instinct is understandable, it can come at a cost. Over time, isolation and inactivity can chip away at physical fitness, reduce resilience and make it harder to recover from illness or cope with stress. The role of exercise Exercise is good for everyone but for people living with CLL, it can be life-changing. Our research shows that physical activity is strongly linked to fewer symptoms and a better quality of life. Fatigue, the most common and often most debilitating symptom, was significantly lower in people who stayed active. Many also reported reduced pain and a greater sense of physical wellbeing. Cancer-related fatigue isn't just feeling a bit tired. It's a deep, persistent exhaustion that doesn't improve with sleep or rest. The exact biological reasons behind it aren't fully understood, but one thing is clear: regular movement helps. People who are more active tend to feel better – and live better. The good news is that even gentle activity can make a difference. Low-intensity activities are safe for almost everyone and come with meaningful health benefits. Walking, yoga, swimming – anything that gets you moving – can help ease symptoms. In fact, research shows that just 12 weeks of regular exercise can reduce fatigue and improve day-to-day wellbeing. People with additional health concerns, such as heart disease, diabetes or bone conditions, should take extra care. It's always a good idea to speak to a doctor or physiotherapist before starting a new routine. The PAR-Q+ (physical activity readiness questionnaire) is a helpful tool to assess whether it's safe to begin exercising. Once cleared, the goal is to work up to the recommended activity levels: 150–300 minutes of moderate activity a week (like brisk walking or cycling) or 75–150 minutes of vigorous activity (like jogging or swimming), along with two sessions of muscle-strengthening activities per week. Start slowly and build gradually. Because people with CLL are immunocompromised, it's important to reduce infection risks while staying active. That might mean exercising outdoors, avoiding crowds, wearing a mask, or choosing quieter times at the gym. But, as long as precautions are taken, the benefits of movement far outweigh the risks. Benefits of keeping active In one of our pilot studies, people with CLL who had not yet started treatment showed smaller increases in tumour cell counts after 12 weeks of exercise. Their immune systems also appeared more robust, with stronger responses to abnormal cells. This research is still in its early stages, but it's encouraging to see that exercise doesn't appear to accelerate disease progression – and might even help to slow it. The biggest improvements were seen in people who started off with the worst symptoms or poorest physical condition. In other words, those with the most to gain, gained the most. Older adults, in particular, seemed to benefit from even modest activity. People receiving treatment were generally less active and reported lower quality of life than those who weren't but their symptom levels were similar. That suggests physical activity might offer especially meaningful benefits for people going through treatment. Exercise is already a well-established part of care for people with solid tumours such as breast or bowel cancer. What's different about CLL is that many people don't receive treatment for years – yet still experience symptoms and lower quality of life. Our study shows that physical activity matters just as much for this group. Whether someone is on active monitoring or undergoing treatment, staying active can help ease symptoms, boost energy and improve daily life. It's a powerful reminder that even small steps can make a big difference and that living well with CLL isn't just about waiting for treatment. It's about reclaiming strength, mobility and agency, one movement at a time.
